Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: GlaxoSmithKline 1Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: GlaxoSmithKline 1Q11

Pharmaceutical sales were $8.4 billion in the quarter (-12%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline 1Q11

1Q Revenues: $10.5 billion (-9%)

1Q Earnings: $3.3 billion (flat)

Comments: Pharmaceutical sales were $8.4 billion in the quarter (-12%). Avandia sales were down 45% to $145 million. Seretide/Advair sales were flat at $2.0 billion. Flixotide/Flovent sales were $323 million (+6%). Valtrex sales were $144 million (-48%), as generics ate away at its base. Lamictal sales were $182 million (-3%). Avodart sales were $266 million (+23%). Lovaza sales were $203 million (+22%). Augmentin sales were $299 million (+20%). Vaccine sales were $1.2 billion, down 5%. Pandemic flu vaccines sales were $8.0 million in the quarter, compared to $1.1 billion in 1Q10.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters